Title:
NEW CRYSTAL FORM OF BENZAMIDE COMPOUND AND DIHYDROCHLORIDE THEREOF, AND PREPARATION METHOD THEREFOR
Document Type and Number:
WIPO Patent Application WO/2022/007752
Kind Code:
A1
Abstract:
The present invention relates to the field of chemical medicines, and particularly to a new crystal form of a free base and dihydrochloride of benzamide compounds, and a preparation method therefor. Provided in the present invention are a method for preparing dihydrochloride crystal form J, dihydrochloride crystal form M, dihydrochloride crystal form E, dihydrochloride crystal form F, dihydrochloride crystal form H, dihydrochloride crystal form N, dihydrochloride crystal form Q, dihydrochloride crystal form S, dihydrochloride crystal form T, dihydrochloride crystal form K and free base crystal form A, free base crystal form B and free base crystal form C of a compound of formula (I), and the use thereof. Dihydrochloride crystal form J, dihydrochloride crystal form M, dihydrochloride crystal form E, dihydrochloride crystal form F, dihydrochloride crystal form H, dihydrochloride crystal form N, dihydrochloride crystal form Q, dihydrochloride crystal form S, dihydrochloride crystal form T, dihydrochloride crystal form K and free base crystal form A, free base crystal form B and free base crystal form C of the compound of formula (I) provided in the present invention have advantages in terms of at least one of the following aspects: solubility, melting point, stability, dissolution rate, hygroscopicity, adhesion, fluidity, bioavailability, processing performance, purification effect, preparation production, safety etc., which provides a new better choice for the preparation of a pharmaceutical preparation containing a free base of the compound of formula (I) and the dihydrochloride thereof, and is of great significance to drug development.
Inventors:
LU XIA (CN)
ZHANG XIAOYU (CN)
ZHANG XIAOYU (CN)
Application Number:
PCT/CN2021/104559
Publication Date:
January 13, 2022
Filing Date:
July 05, 2021
Export Citation:
Assignee:
CRYSTAL PHARMATECH CO LTD (CN)
International Classes:
C07D401/10; A61K31/53; A61P35/00; C07D253/07; C07D487/04
Domestic Patent References:
| WO2016011658A1 | 2016-01-28 |
Foreign References:
| CN102083814A | 2011-06-01 | |||
| CN110526916A | 2019-12-03 | |||
| CN101641093A | 2010-02-03 | |||
| CN104245701A | 2014-12-24 | |||
| CN106714784A | 2017-05-24 | |||
| CN108697794A | 2018-10-23 | |||
| CN106794180A | 2017-05-31 | |||
| US20160030559A1 | 2016-02-04 |
Other References:
X. LIU, Q. WANG, G. YANG, C. MARANDO, H. K. KOBLISH, L. M. HALL, J. S. FRIDMAN, E. BEHSHAD, R. WYNN, Y. LI, J. BOER, S. DIAMOND, C: "A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, vol. 17, no. 22, 15 November 2011 (2011-11-15), pages 7127 - 7138, XP055030185, ISSN: 10780432, DOI: 10.1158/1078-0432.CCR-11-1157
Download PDF:
Previous Patent: CEILING CASSETTE UNIT AND AIR CONDITIONER
Next Patent: DIGITAL TWIN MODELING METHOD ORIENTED TO MOBILE ROBOT MILLING PROCESSING
Next Patent: DIGITAL TWIN MODELING METHOD ORIENTED TO MOBILE ROBOT MILLING PROCESSING